CGEM

Cullinan Therapeutics, Inc.

Contracts

Total Value

Stock Metrics

23.2%

Short % Float

19.2d to cover · High squeeze

1.1%

Inst % Float

10 holders · 2026-06-30

Lynx1 Capital Mana

Top Holder

14.6% of float

44.3M sh

Public Float

35/100

Dilution Score

Medium

24 mo

Cash Runway

Verified regulatory filings & proprietary analysis.

Dilution Risk

35/100

MEDIUM

Inst: 1.06% · Top: Lynx1 Capital Management Lp

Biotech Analytics

Oncology

17.13

Squeeze risk: HIGHBiotech Grade: F

Insider Buying0

Publications100

Dilution Risk35

Clinical Trials17

Short Interest70